| Anti-inflammatory (anti-osteoarthritic): –decreasing the interleukin (IL)-1β-stimulated expression of MMP-3 and MMP-13; –inhibition of the IL-1β-induced expression of iNOS and COX-2, and the production of PGE2 and NO; inhibition of IL-1β-induced NF-κB activation | In vitro Human Articular Chondrocyte Culture | [97] |
| Anti-inflammatory: –inhibition of nitric oxide (NO) and prostaglandin E 2 (PGE 2) production by inhibiting iNOS and COX-2 expression; –inhibition of LPS-stimulated production of TNF-α and IL-1β; –activation of LXRα (liver X receptor α) and inhibition of LPS-induced NF-κB activation | In vitro BV2 microglial cells | [98] |
| Antioxidative and anti-inflammatory: –decreasing reactive oxygen species (ROS) generation; –inhibition of the expression of inducible nitric oxide synthase (iNOS) and NADPH oxidase (NOX); –decreasing the production of tumor necrosis factor-α (TNF-α), interleukin 6 (IL-6), and IL-1β; –preventing phosphorylation of nuclear factor-κB (NF-κB) subunit p65 and degradation of NF-κB inhibitor α (IκBα) | In vitro Rat vascular smooth muscle cells (RVSMCs); | [99] |
| Anti-inflammatory: –decreasing paw edema; –increasing the activities of catalase (CAT), superoxide dismutase (SOD), and glutathione peroxidase (GPx) in liver tissue; –attenuating the level of thiobarbituric acid reactive substances (TBARS) in the edematous paw; –decreasing the nitric oxide (NO) levels at the serum level and diminishing the serum tumor necrosis factor (TNF-α); –decreasing the expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) | Ex vivo and in vivo RAW264.7 macrophages and λ-carrageenin-induced hind paw edema model in mice | [37] |
| Anti-inflammatory: –reducing the production of NO, prostaglandin E2 (PGE2), and tumor necrosis factor-α (TNF-α) induced by LPS; –suppressing the LPS-induced expression of inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), and TNF-α at the mRNA and protein levels; –decreasing DNA binding of nuclear factor kappa B(NF-kB) and nuclear translocation of the p65 and p50 subunits of NF-kB; –suppressing degradation and phosphorylation of inhibitor of kappa B-Alpha | In vitro LPS stimulated RAW264.7 cells | [100] |
| Anti-inflammatory/antinociceptive (20–30 mg/kg) | In vivo Writhing Assay; Hot-Plate Test; Carrageenan-Induced Edema in Sprague–Dawley Rats | [32] |
| Anti-inflammatory: –inhibition of the production of interleukin-6 and interleukin-8; –inhibition of TLR4 (Toll-like receptor 4) expression; –inhibition of activation of nuclear factor kappa B (NF-κB); –inhibition of activation of mitogen-activated protein kinases (MAPKs) | In vitro LPS-stimulated human gingival fibroblasts (HGFs) | [101] |
| Anti-inflammatory: –inhibition of LPS-induced NO production | In vitro | [69] |
| Anti-inflammatory: –inhibitory effect on IFN-γ secretion –inhibition of COX-1 and COX-2 –apoptosis-inducing effect | In vitro LPS-stimulated Raw 264.7 macrophage | [61] |
| –Anti-inflammatory; –Potent inhibitory effect on Epstein-Barr virus early antigen (EBV-EA) activation; –Antitumor-promoting activity (strong) | In vivo:
–TPA-induced ear edema inflammation in mice; –two-stage carcinogenesis test of mouse tumor; In vitro EBV-EA activation experiment | [42] |
| –Cytotoxic activity against the HeLa cell line; –Antidiabetic activity –Inhibition of PTP1B (Protein tyrosine phosphate) | In vitro | [29] |
| Cytotoxic to sensitive and multidrug resistant leukemia cell lines; Active toward a multidrug resistant (MDR) leukemia cell line overexpressing glycoprotein-P (P-gp) | In vitro (anti-MDR activity in Lucena-1, a leukemia cell line that overexpresses P-gp and presents cross resistance to several unrelated cytotoxic drugs) | [16] |
| Cytotoxic | In vitro HCT-8, A549, P-388, L-1210 tumor cell lines | [58] |
| –Cytotoxicity in human oral tumor cell lines: human salivary gland tumor and human oral squamous cell carcinoma –Inhibition of the activation of Epstein–Barr virus early antigen (EBV-EA) | In vivo EBV genome-carrying lymphoblastoid cells In vitro human oral squamous cell carcinoma (HSC-2), human salivary gland tumor (HSG) | [38] |
| Antidiabetic and antihyperlipidemic: –Antihyperlipidemic: decreasing gene expressions of fatty acids, increasing the content of phosphorylated AMPK-α in liver and adipose tissue, inhibition of DGAT 1 expression, and decreasing the level of triglycerides in blood –Antidiabetic: down-regulation of phosphenolpyruvate carboxykinase (PEPCK), improving insulin sensitization (at 1.0 g/kg), and decreasing the expression of the hepatic and adipose 11-β-hydroxysteroid dehydroxygenase (11β-HSD1) gene | In vivo high-fat fed C57BL/6J mice | [4] |
| Hypoglycemic: decreasing the blood glucose level (at 10 mg/kg) | In vivo normoglycemic Wistar rats | [79] |
| Hypoglycemic effect (at 30 mg/kg): –decreasing glucose levels in normal rats; –increasing fasting plasma insulin levels Acute toxicity not observed (at 600 mg/kg, intraperitoneally) | In vivo normoglycemic, hyperglycemic, and streptozotocin-induced diabetic Wistar rats | [80] |
| Hypoglycemic effect: –direct stimulation of insulin secretion by pancreatic islets of Langerhans | In vitro pancreatic islets of Langerhans isolated from fed Wistar rats | [102] |
| Antidiabetic: –inhibition of alfa-glucosidase | In vitro | [78] |
| Antidiabetic and antihyperlipidemic activity: –lowering blood glucose, triglycerides, free fatty acids, leptin levels; –decreasing the area of adipocytes and ballooning degeneration of hepatocytes; –reducing visceral fat mass, reducing hepatic triacylglycerol contents; –enhancing skeletal muscular Akt phosphorylation and increasing insulin sensitivity; –decreasing blood triglycerides by down-regulation of the hepatic sterol regulatory element binding protein-1c (SREBP-1c) and apolipoprotein C-III (apo C-III) and increasing the expression of peroxisome proliferator activated receptor (PPAR)-α | In vivo C57BL/6J mice with induced type 2 diabetes and hyperlipidemia | [103] |
| Influencing the processes present in vasculoproliferative diseases (diseases related to vascular smooth muscle cell (VSMC) abnormal proliferation): –increasing apoptosis of serum-deprived A7r5 cells and inhibiting A7r5 cell proliferation; –rapid induction of significant modifications in the vascular smooth muscle cell (VSMC) phenotype; –inhibition of VSMC proliferation and VSMC cell death | In vitro Clonal rat embryonic VSMCs (A7r5) and human umbilical vein endothelial cells (HUVEC) | [93] |
| Anti-melanogenesis effect (melanin synthesis inhibitory activity with less cytotoxicity) Antibacterial activity against Propionibacterium acnes
Promotion of skin collagen synthesis | In vitro Mouse melanoma cell line B16; Propionibacterium acnes (NBRC 107605) | [104] |
| Hepatoprotective (preventing fulminant hepatic failure): –blocking the NF-κB signaling pathway for anti-inflammatory response (alleviating the pro-inflammatory cytokines, e.g., TNF-α and NO/iNOS by inhibiting nuclear factor-κB activity); –inhibition of hepatic lipid peroxidation; –decreasing serum aminotransferase and total bilirubin activities; –attenuating hepatocellular apoptosis | In vivo lipopolysaccharide/d-galactosamine-induced acute hepatic failure in male C57BL/6 mice | [77] |
| Hepatoprotective: –inhibition of the production of pro-inflammatory factors such as: tumor necrosis factor-alpha (TNF-α), interleukin-1beta (IL-1β), and IL-6; –inhibition of inducible NO synthetase (iNOS) and cyclooxygenase-2 (COX-2); –inhibition of nuclear factor –κB (NF-κB) activation; –inhibition of the activation of mitogen-activated protein kinases (MAPKs); –retention of enzymes (essential for the antioxidative properties of liver): superoxidase dismutase (SOD), glutathione peroxidase (GPx), catalase (CAT) | In vivo Acetaminophen-induced hepatotoxicity in male ICR mice | [105] |
| Protective effect against liver fibrosis: –inhibition of the activation of hepatic stellate cells; –reducing aspartate aminotransferase, alanine aminotransferase, and total bilirubin activity; –inhibition of expression of collagen type I and III; alleviation of collagen-based extracellular matrix deposition; –promoting cell apoptosis via blocking of the PI3K/Akt/mTOR and NF-κB signaling pathways | In vitro Hepatic stellate cells (HSCs) stimulated with platelet-derived growth factor-BB | [106] |
| Cardioprotective (protective effects on hypoxia/reoxygenation (H/R)-induced cardiomyocyte injury) | In vitro Neonatal rat cardiomyocytes subjected to hypoxia/reoxygenation (H/R) insult | [18] |
| Anti-hypoxic (protecting vascular endothelial cells against hypoxia-induced damage via the PI3K/AKT and ERK 1/2 signaling pathway) | In vitro (EA.hy926 cells) | [107] |
| Antiproliferative: –causing apoptosis and G0/G1 phase arrest in cancer cell lines; –induction of cell cycle arrest via changing the cyclin D1 and cyclin-dependent kinase 4 mRNA expression levels; –down-regulation of the NF-kappa-B cell survival pathway and the expression level of phosphorylated ERK (extracellular signal-regulated kinase) | In vitro Cancer cell lines: human hepatoma cells HepG-2 and Bel-7402, lung cancer cell A549, breast cancer cell MCF-7 Normal LO2 cell line | [108] |
| Antiproliferative | In vitro | [85] |
| Anti-cancer (anti-hepatocellular carcinoma activity): –decreasing cell viability, colony formation, and cell migration; –induction of apoptosis; –changing the levels of caspase-3 and poly ADP-ribose polymerase expression | In vitro Hepatocellular carcinoma cells (HepG2, Bel-7405, Sk-hep-1) | [39] |
| Anti-cancer: –induction of cell cycle arrest; –enhancement of ROS production; –targeting the mTOR/PI3K/AKT signaling pathway in cisplatin-resistant human cervical cancer cells | In vitro Cisplatin-resistant human cervical cancer cells (HeLa cells) | [95] |
| Anti-osteoarthritic (inhibition of IL-1β-induced chondrocyte apoptosis by activation of the PI3K/Akt signaling pathway): –inhibition of IL-1β induced cytotoxicity and apoptosis in chondrocytes; –increasing B-cell lymphoma (Bcl)-2 expression; –decreasing capsase-3 activity and Bax expression; –increasing the expression of p-PI3K and p-Akt in IL-1β-induced chondrocytes | In vitro IL-1β-treated human osteoarthritic chondrocytes | [96] |
| Antinociceptive (anti-allodynic) | In vivo two models of chronic pain (neuropathic pain and inflammatory pain) in mice | [92] |
| Antibacterial | In vitro | [51] |
| Antibacterial and antibiofilm effect: –inhibition of growth of P. aeruginosa; –depolarization of bacterial P. aeruginosa membrane; –inhibition of biofilm formation due to suppressed secretion of pyoverdine and suppressed secretion of protease and swarming motility of P. aeruginosa | In vivo Mouse model of catheter infection for evaluation of antibiofilm activity and BALB/c mouse model for determination of in vivo toxicity
In vitro P. aeruginosa cultures; murine macrophage cell line (RAW 264.7) for cytotoxicity assay | [91] |
| Antibacterial against S. aureus
Antifungal against C. albicans | In vitro | [28] |
| Antibacterial against S. aureus | In vitro | [81] |
| Bacteriostatic against S. aureus: –inhibition of extracellular protease production resulting in inhibition of S. aureus growth | In vitro | [66] |
| Antivirus: inhibition of virus HIV-1 protease | In vitro | [71] |
| Insect antifeedant | In vivo Spodoptera littoralis L6 larvae | [41] |
| Neuroprotective: –protecting against neurotoxicity (preventing neuronal loss); –blocking MPP+-induced apoptosis; –inhibiting intracellular accumulation of reactive oxygen species (ROS); –protecting from neuronal death through reversing the inhibition of the PI3-K/Akt/GSK3b pathway | In vitro Parkinson’s disease cellular model: MPP+-induced neurotoxicity in human neuroblastoma SH-SY5Y cells | [109] |
| Neuroprotective: –decreasing amyloid plaque deposition; –reducing microglial activation and decreasing the secretion of pro-inflammatory factors; –suppressing the production of pro-inflammatory markers and the nuclear translocation of nuclear factor-κB (NF-κB); –reducing inhibited neurotoxicity and improving neuron survival | In vivo Amyloid β precursor protein (APP)/presenilin 1 (PS1) transgenic mice In vitro BV2 microglia cells | [94] |